Cancer is one of the deadliest diseases worldwide. Recent statistics have shown that
metastases and tumor relapse are the leading causes of cancer‐associated deaths. While …

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …

Platinum-based anticancer drugs occupy a crucial role in the treatment of various malignant
tumours. However, the efficacy and applicability of platinum drugs are heavily restricted by …

The platinum-based drugs cisplatin, carboplatin, and oxaliplatin belong to the most widely
used chemotherapeutics in oncology, showing clinical efficacy against many solid tumors …

Oxaliplatin was the third Pt-based anticancer drug to be clinically used worldwide. It exhibits
a broad spectrum of anticancer activity and was the first to be approved for the treatment of …

ABSTRACT PT-112 is a novel platinum-pyrophosphate conjugate under clinical
development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a …

The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of
cisplatin and it remains just as useful now as it did back then, especially for the treatment of …

The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a
spectacular translational science achievement. The basic research observations that led to …

Background PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell
death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT …

Metal complexes have shown great potential in cancer immunotherapy. This review briefly
introduces the basic concepts and strategies of cancer immunotherapy and summarizes the …